Skip to content

Chronic High‐Dose Ketamine Fails to Induce a Cystitis‐Like Phenotype in Mice Despite High Urinary Metabolite Levels

Jill Dewez, Ashlee Caldwell, Laura Schillebeeckx, Margot De Vis, Sylvia João Poseiro Coutinho Pinto, Evy Van den Broek, Véronique Hendrickx, Katrien Luyten, Marcella Baldewijns, Jan Tytgat, Thomas Voets, Wouter Everaerts

Neurourology and urodynamics October 21, 2026 DOI: 10.1002/nau.70483 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Controlled animal experiment Peer reviewed
Sample size 40
Population Male and female C57BL/6 J mice
Intervention Ketamine
Dose 100 mg/kg
Duration 12 weeks
Measures spontaneous voiding assays, von Frey filaments, nesting and open field assays, histopathological analysis, LC-QTOF/MS
Topics Esketamine Ketamine
Key findings Chronic high-dose ketamine (100 mg/kg intraperitoneally for 12 weeks) produced high urinary and plasma concentrations of ketamine and its metabolites but no significant differences from saline controls in voiding behavior, suprapubic mechanical sensitivity, natural behavior, or bladder and kidney histopathology. The authors conclude that this mouse strain does not develop a robust ketamine-induced cystitis phenotype, highlighting limitations of rodent models for recapitulating human ketamine-induced cystitis.

Abstract

ABSTRACT:

Aims: Ketamine‑induced cystitis (KIC) is a severe complication of chronic ketamine misuse, yet the underlying mechanisms remain poorly understood. Established rodent models have demonstrated variable changes in voiding behavior and bladder histology, without exploring the sensory mechanisms underlying altered voiding and pain at all. This study aimed to establish a murine model of chronic ketamine‐induced cystitis to investigate changes in pain behavior and sensory signaling.

Methods: Male and female C57BL/6 J mice received intraperitoneal ketamine (100 mg/kg, n = 20) or saline ( n = 20) for 12 weeks. Urine and plasma ketamine, norketamine, and dehydronorketamine concentrations were determined using LC‐QTOF/MS. Voiding behavior was assessed fortnightly using spontaneous voiding assays, suprapubic mechanical sensitivity was evaluated using von Frey filaments, and wellbeing was assessed using nesting and open field assays. Finally, histopathological analysis was performed on bladder and kidney tissues.

Results: Despite high urinary and plasma concentrations of ketamine, norketamine, and dehydronorketamine, ketamine‐treated mice showed no significant differences in voiding behavior, suprapubic sensitivity, natural behavior, or bladder and kidney histopathology compared with controls.

Conclusion: Chronic high‐dose ketamine treatment did not induce a robust phenotype of ketamine‐induced cystitis in C57BL/6 J mice, highlighting limitations of using rodent models for recapitulating human ketamine‑induced cystitis.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Twelve weeks of high-dose ketamine produced high urinary and plasma drug and metabolite levels but no differences from saline in voiding behavior, suprapubic sensitivity, wellbeing, or bladder and kidney histopathology.

    Synthesized

Comparable studies

Other preclinical and animal studies on ketamine, most cited first.

Citations in the library

Explore topics